This article is more than 5 years old. Information may no longer be current.

Eyevance acquires worldwide rights to corneal epithelial defect candidate Nexagon

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Eyevance Pharmaceuticals has acquired worldwide licensing rights to Nexagon, a 30-base antisense oligomer treatment candidate for persistent corneal epithelial defect, according to a press release.

A worldwide licensing agreement with OcuNexus Therapeutics will allow Eyevance to continue development of Nexagon, an unmodified antisense oligodeoxynucleotide that inhibits a cell membrane hemichannel forming protein and re-establishes limbal microvasculature, promoting regeneration of the corneal epithelium, the release said.

The company is funding a pivotal clinical trial that is expected to start in the first quarter of 2019.

“Nexagon is a unique product candidate that, if successfully developed, stands to benefit an underserved patient population,” Jerry St. Peter, Eyevance CEO and director, said in the release.